InsiderTrades.com logo
50-year Wall Street legend: “Sell this tech stock NOW”
From Chaikin Analytics   |   Ad
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
You can watch for it for free, right here.
Timothy Eugene Sullivan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Timothy Sullivan Biography and Net Worth

CFO of Apellis Pharmaceuticals
Tim has served as our chief financial officer since October 2017. From January 2014 to October 2017, Tim served as partner at Aju IB Investment, a venture capital firm, at which he led the firm’s investments in life sciences companies. Prior to joining Aju IB Investment, from December 2011 to January 2014, Tim was managing director, head of life sciences investment banking at RBS Citizens. Tim was an observer on our board of directors from November 2014 until October 2017. Tim has previously served as a director of G1 Therapeutics, Inc. and Molecular Templates, Inc. Tim received his MBA degree from the Columbia Business School and his BA degree in biology from Harvard University.

What is Timothy Eugene Sullivan's net worth?

The estimated net worth of Timothy Eugene Sullivan is at least $2.87 million as of April 1st, 2024. Mr. Sullivan owns 93,338 shares of Apellis Pharmaceuticals stock worth more than $2,872,010 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Sullivan may own. Additionally, Mr. Sullivan receives a salary of $793,430.00 as CFO at Apellis Pharmaceuticals. Learn More about Timothy Eugene Sullivan's net worth.

How old is Timothy Eugene Sullivan?

Mr. Sullivan is currently 53 years old. There are 8 older executives and no younger executives at Apellis Pharmaceuticals. The oldest executive at Apellis Pharmaceuticals is Mr. James G. Chopas CPA, VP, Corporate Controller & Chief Accounting Officer, who is 57 years old. Learn More on Timothy Eugene Sullivan's age.

What is Timothy Eugene Sullivan's salary?

As the CFO of Apellis Pharmaceuticals, Inc., Mr. Sullivan earns $793,430.00 per year. There are 2 executives that earn more than Mr. Sullivan. The highest earning executive at Apellis Pharmaceuticals is Dr. Cedric Francois M.D., Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,440,000.00 per year. Learn More on Timothy Eugene Sullivan's salary.

How do I contact Timothy Eugene Sullivan?

The corporate mailing address for Mr. Sullivan and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Timothy Eugene Sullivan's contact information.

Has Timothy Eugene Sullivan been buying or selling shares of Apellis Pharmaceuticals?

Timothy Eugene Sullivan has not been actively trading shares of Apellis Pharmaceuticals during the last quarter. Most recently, Timothy Eugene Sullivan sold 4,000 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $58.66, for a transaction totalling $234,640.00. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares of the company's stock, valued at $5,475,207.08. Learn More on Timothy Eugene Sullivan's trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 32 times. They sold a total of 591,910 shares worth more than $33,301,080.32. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 9/16/2024.

Timothy Eugene Sullivan Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/1/2024Sell4,000$58.66$234,640.0093,338View SEC Filing Icon  
3/1/2024Sell6,000$63.22$379,320.0093,338View SEC Filing Icon  
2/12/2024Sell1,431$67.77$96,978.8793,338View SEC Filing Icon  
1/22/2024Sell3,551$65.00$230,815.0095,675View SEC Filing Icon  
1/16/2024Sell2,235$66.81$149,320.3599,226View SEC Filing Icon  
7/3/2023Sell6,779$89.97$609,906.6377,713View SEC Filing Icon  
6/5/2023Sell69,779$88.80$6,196,375.2077,713View SEC Filing Icon  
8/29/2019Buy11,699$29.71$347,577.2911,699View SEC Filing Icon  
See Full Table

Timothy Eugene Sullivan Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Timothy Eugene Sullivan's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $30.77
Low: $27.71
High: $30.99

50 Day Range

MA: $29.06
Low: $26.18
High: $37.62

2 Week Range

Now: $30.77
Low: $24.34
High: $73.80

Volume

2,913,486 shs

Average Volume

1,904,351 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87
50-year Wall Street legend: “Sell this tech stock NOW”
From Chaikin Analytics   |   Ad
Something very strange is happening to U.S. stocks following President Trump's victory... And this could spell disaster for some of America's favorite tech companies.
You can watch for it for free, right here.